The randomized, prospective, multicenter, controlled trial involved 136 Barrett’s esophagus patients with low-grade dysplasia. After the last endoscopy visit, 90 percent of the patients treated with ablation demonstrated no signs of Barrett’s esophagus tissue.
More Articles on Gastroenterology:
8 Trends Shaping the Present & Future of Gastroenterology
PENTAX Launches Video Processor With PENTAX i-SCAN
Vision-Sciences Names Howard Zauberman Interim CEO
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
